KANTAR HEALTH BLOG

While unique challenges exist in today's healthcare growth markets, there are many opportunities for pharma companies to flourish in these still largely un-tapped markets. To achieve commercial success, a local presence and a comprehensive understanding of local market nuances are a must for developing and executing a highly informed market access strategy. This allows companies to address foreseen and unforeseen market barriers, secure positions on formularies, and ultimately improve the health and well-being of the people in these countries and regions. This formula for success is especially true for pharma companies looking to do business, or expand business, in India.

Navigating through compliance issues and regulatory mazes when designing a patient study is undoubtedly difficult, but success can be more easily achieved through a well-conceived, high-quality approach.

Having taken effect in May 2018, the GDPR imposes new obligations on organizations that process the personal data of EU residents, including research agencies, pharmaceutical manufacturers and data analytic companies.

The revolutionary new uses of the “share of preference” measurement is a eureka moment in marketing science for the pharmaceutical industry. Combined with a brand’s existing market share, share of preference can now be used to look at where a brand’s market share currently stands, where it could rise to, and most importantly how to get there by pulling the lever and minimizing the impact of barriers!

Brazil is bursting with opportunities for pharma companies- but only those who understand this growth market's nuances will succeed.